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Abstract: Controversy has arisen among the public and in the media regarding the health 
effects of fish intake in adults. Substantial evidence indicates that fish consumption reduces 
coronary  heart  disease  mortality,  the  leading  cause  of  death  in  developed  and  most 
developing  nations.  Conversely,  concerns  have  grown  regarding  potential  effects  of 
exposure to mercury  found in some fish. Seafood species are also rich in selenium, an 
essential trace element that may protect against both cardiovascular disease and toxic effects 
of mercury. Such protective effects would have direct implications for recommendations 
regarding  optimal  selenium  intake  and  for  assessing  the  potential  impact  of  mercury 
exposure from fish intake in different populations. Because fish consumption appears to 
have important health benefits in adults, elucidating the relationships between fish intake, 
mercury and selenium exposure, and health risk is of considerable scientific and public 
health relevance. The evidence for health effects of fish consumption in adults is reviewed, 
focusing on the strength and consistency of evidence and relative magnitudes of effects of 
omega-3 fatty acids, mercury, and selenium. Given the preponderance of evidence, the focus 
is on cardiovascular effects, but other potential health effects, as well as potential effects of 
polychlorinated biphenyls and dioxins in fish, are also briefly reviewed. The relevant current 
unanswered questions and directions of further research are summarized. 
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1. Introduction 
 
Controversy  is  present  among  the  public  and  in  the  media  regarding  the  health  effects  of  fish 
consumption. Considerable evidence indicates that consumption of fatty fish reduces coronary heart 
disease (CHD) mortality [1] the leading cause of death in developed and most developing nations. On 
the other hand, concerns regarding potential harm from exposure to mercury [2-6], a heavy metal present 
in some fish species, have tempered the perception of fish as a healthy food. Very high levels of mercury 
exposure are known to cause sensorimotor symptoms in adults, which are often reversible when mercury 
exposure is reduced [7-9]. However, for the great majority of individuals, the  main concern is the 
potential health effects of chronic low-level mercury exposure from modest fish consumption. Seafood 
species are also rich in selenium, an essential dietary trace element that plays an important role in 
antioxidant defense systems and may protect against both cardiovascular disease (CVD) and the toxic 
effects of mercury. A protective effect of selenium could directly inform recommendations relating to 
both optimal selenium intake and the potential impact of mercury exposure from fish consumption in 
selenium-replete  vs.  selenium-deficient  populations.  Because  fish  consumption  appears  to  have 
significant health benefits, elucidating the relationship  between  fish  intake,  mercury  exposure, and 
health risk is of considerable scientific and public health importance. The evidence for health effects of 
fish consumption in adults is reviewed, particularly the strength and consistency of evidence and relative 
magnitudes  of  cardiovascular  effects  of  marine  omega-3  polyunsaturated  fatty  acids  (n-3  PUFA), 
mercury,  and  selenium  in  fish.  Other  potential  health  effects,  including  potential  effects  of 
polychlorinated biphenyls (PCBs) and dioxins in fish, are also briefly reviewed. This article does not 
consider possible cardiovascular benefits of plant-based omega-3 fatty acids, which have been reviewed 
elsewhere [10]. This review also focuses on health effects in adults – the potential effects on infant 
neurodevelopment, and corresponding recommendations for women who are or may become pregnant, 
have been reviewed elsewhere [1,11,12].  
 
2. Fish and Cardiovascular Risk 
 
Consumption  of  fish  or  fish  oil  favorably  affects  several  cardiovascular  risk  factors (Figure  1) 
[13-24]. Changes in most risk factors are generally evident within weeks of changes in consumption and 
may result from altered cell membrane fluidity and receptor responses following incorporation of n-3 
PUFA into cell membrane phospholipids [25,26] as well as direct binding of n-3 PUFA to cytosolic 
receptors that regulate gene transcription [27]. These physiologic effects of n-3 PUFA have varying 
dose-responses and time-responses of effect [1]. For example, at typical dietary intakes (< 1 g/d of n-3 
PUFA), anti-arrhythmic effects appear to predominate, with such effects reducing the risk of cardiac 
death within weeks to months. At higher levels of consumption, maximum antiarrhythmic benefits 
appear to have been achieved, but now other physiologic effects of n-3 PUFA consumption (Figure 1) 
may begin to influence other clinical outcomes, such as stroke or nonfatal CVD events. Time courses of 
benefit also vary;  for instance, some of these effects (such as triglyceride-lowering)  might require 
months or years of consumption before an impact on incidence of clinical outcomes are evident. These 
benefits on intermediate risk factors are compelling, but inference for health effects of an exposure on 
chronic disease outcomes requires confirmation in studies of actual disease endpoints in humans. Int. J. Environ. Res. Public Health 2009, 6                 
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Figure 1. Schema of physiologic effects of n-3 PUFA consumption. The strength of effect 
denotes the relative impact of n-3 PUFA intake on clinical risk by means of the physiologic 
effect (e.g., triglyceride-lowering), whereas the time course to alter clinical events denotes 
the expected duration of intake for the benefits on the physiologic effect to be manifested in 
improved  disease  outcomes.  For  instance,  the  dose-response  for  anti-arrhythmic  effects 
appears to be initially steep with a subsequent plateau, and effects on disease outcomes may 
be seen in weeks to months, whereas the dose-response for triglyceride-lowering is more 
gradual and monotonic, and effects on disease outcomes may require months to years of 
intake.  Potentially  important  effects  of  n-3  PUFA  on  endothelial,  autonomic, 
anti-inflammatory, and diastolic responses are not shown because dose- and time-responses 
of these effects are less well-established. Physiologic effects are not necessarily exclusive: 
e.g., anti-arrhythmic effects may be partly mediated by effects on blood pressure (BP) or 
heart rate. Reproduced with permission from Mozaffarian and Rimm [1]. 
 
 
This evidence exists. Results of case-control studies, prospective cohort studies, and randomized 
controlled trials each indicate that modest consumption of fish or fish oil lowers the risk of cardiac 
mortality, specifically CHD death and sudden cardiac death [1]. This effect appears to be nonlinear: 
compared  with  little  or  no  intake,  modest  consumption  (~250  mg/d)  of  the  marine  n-3  PUFA 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) significantly  lowers risk of cardiac 
mortality, whereas higher intakes do not substantially further lower risk, suggesting a threshold of  
effect [1]. The similarity of findings between observational studies of fish consumption and randomized 
controlled trials of n-3 PUFA supplementation suggests that, at least for cardiac mortality, much of the 
benefit of fish intake is related to the n-3 PUFA content. Consistent with this, when different types of 
fish meals are considered, lower risk is more strongly related to intake of fatty (oily or dark meat) fish, 
compared with lean (white meat) fish [28,29].
 The quantity of fish servings needed to consume an 
average of 250 mg/d EPA+DHA varies depending on the particular fish species, but for fatty fish (e.g., 
anchovies, herring, salmon, sardines, trout, white tuna) is ~1-2 servings/week (Figure 2).  Int. J. Environ. Res. Public Health 2009, 6                 
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Figure 2. The number of 3.5 oz (100 g) fish servings per week needed to provide an average 
of 250 mg/day of the marine n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA). Based on data from Mozaffarian and Rimm [1].  
 
 
The strength and consistency of the evidence, and the magnitude of the benefit, for lowering of 
cardiac mortality by fish consumption are each notable. The risk reduction is supported by consistent 
evidence  from  experimental  studies  and  randomized  trials  investigating  effects  of  fish  or  fish  oil 
consumption  on  cardiovascular  risk  factors;  case-control  studies  evaluating  fish  consumption  or 
objective biomarkers of n-3 PUFA intake and risk of cardiac outcomes; prospective studies of habitual 
fish consumption and cardiac outcomes that have followed hundreds of thousands of people for many 
years across a range of countries; and randomized controlled trials of fish or fish oil consumption that 
have enrolled thousands of subjects and demonstrated reductions in clinical events [1]. The magnitude of 
the benefit is also considerable: pooling of the prospective studies and controlled trials indicates that, 
compared  with  no  intake,  modest  consumption  (~250  mg/day  [2¼  calories/day]  of  EPA+DHA, 
equivalent to ~1-2 servings/week of fatty fish) lowers risk of CHD mortality by 36% [1]. Analyses 
restricted to populations free of established heart diease (i.e., primary prevention) demonstrate similar 
results  [30].  Fish  intake  may  also  reduce  the  risk  of  other  cardiovascular  and  noncardiovascular 
outcomes,  including  but  not  limited  to  nonfatal  heart  attacks  [31],  ischemic  stroke  [32],  atrial  
fibrillation [33], cognitive decline [34], and depression [35], but the evidence for these benefits is not yet 
as robust as for CHD death [1].  
 
3. Mercury and Cardiovascular Risk 
 
Mercury is a highly reactive heavy metal that is rarely found as a free element in Nature. In its 
elemental form, it is emitted from coal-burning electric power plants and used in chlorine production, 
dental amalgams, thermometers, and batteries [7,36]. Released into the air, it cycles from rain into 
streams,  lakes,  and  oceans  where  it  is  converted  by  microorganisms  into  organic  methylmercury Int. J. Environ. Res. Public Health 2009, 6                 
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(MeHg). Smaller amounts of inorganic mercury naturally in the environment (e.g., from volcanoes) may 
also be converted by these microorganisms to MeHg. When these microorganisms are ingested, MeHg 
bioaccumulates in the food chain from smaller creatures to larger predators, with tissue concentrations 
depending on the level of local contamination and on the size, lifespan, and predatory nature of each 
creature. Thus, MeHg levels tend to be higher in large, long-lived predators (e.g., shark, swordfish, king 
mackerel,  tilefish);  intermediate  in  medium-sized  predators  (e.g.,  trout,  snapper);  and  lowest  in 
short-lived (e.g., salmon) or smaller (e.g., shrimp, clams) species [1].  
By strongly binding to sulfhydryl groups, mercury can alter the activity of a variety of enzymes, ion 
channels, and receptors [3,7]. In considering public health effects of chronic low-level exposure, the 
primary mercury species of interest is MeHg, which is more reactive and potentially toxic than elemental 
or inorganic mercury [7,36-38]. Elemental mercury is oxidized to mercuric ion, which does not readily 
cross some tissue barriers. Also, inorganic mercury is poorly absorbed in the gastrointestinal tract, 
limiting potential toxicity. In contrast, MeHg is readily absorbed in the gastrointestinal  system and 
actively  transported  into  tissues  by  a  widely  distributed  amino  acid  carrier  protein  following  the 
formation of a methylmercury-cysteine complex. Thus, compared with elemental or inorganic mercury, 
MeHg is more toxic at lower levels of exposure [7]. Additionally, with the exception of  industrial 
accidents or occupational exposures to organic mercury, the  major source of  mercury exposure in 
humans  is  MeHg  from  fish  [7,36,39,40].  Accordingly,  the  Mercury  Study  Report  to  Congress 
concluded, “Assessment of health endpoints, dose-response, and exposure suggests that methylmercury 
is the chemical species of major concern [7].”  
Given their slow growth, mercury levels in toenails or hair provide the best biomarkers of chronic 
mercury exposure. Toenail mercury levels correlate with usual fish intake and, due to stability of most 
individuals’ dietary habits, are reproducible over time (r = 0.56 for toenail mercury samples obtained six 
years apart) [41,42]. This stability is similar to correlations of 0.6 - 0.7 typically observed, over a similar 
time  interval,  for widely used epidemiologic  measures such as blood  pressure [43]. Whereas  both 
organic and inorganic mercury species contribute to total mercury levels, in the absence of unusual 
occupational or environmental exposures to inorganic mercury, MeHg from fish intake is the major 
determinant of  variation  in  total  mercury  levels  in  hair  and  toenails.  For  example,  the  correlation 
between total mercury and MeHg levels in hair is 0.99 [44], and in toenails, this correlation is 0.97 
(unpublished observation, in collaboration with Dr. Shade, Quicksilver Scientific, LLC, Lafayette, CO).  
High exposure to mercury (often much higher than the U.S. reference dose) causes paresthesias, 
ataxia,  and  sensory  symptoms  in  adults,  which  are  often  reversible  when  mercury  exposure  is  
reduced [7-9]. However, few individuals are exposed to such doses, and thus the major public health 
concern for the general population is the potential health effect of chronic low-level mercury exposure 
that could result from modest (up to several servings per week) fish consumption. For example, because 
such chronic low-level mercury exposure may have subtle effects on the developing brain in infants, the 
U.S. Food and Drug Administration and U.S. Environmental Protection Agency have issued specific 
recommendations regarding consumption of a few specific fish species to minimize mercury exposure in 
women who are or may become pregnant, nursing mothers, and young children [12,36].  
Similar recommendations have not been released for the general population, because it is less clear 
that chronic low-level mercury exposure has significant health effects in adults. For example, outside of 
the sensitive period of brain development in the first years of life, current evidence is insufficient to Int. J. Environ. Res. Public Health 2009, 6                 
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conclude that chronic low-level mercury exposure has appreciable neurologic effects. As previously 
reviewed [1,11], in populations exposed to mercury  from  fish consumption, no clinical  neurologic 
effects of mercury exposure are seen (excepting individuals with very high consumption, more than 
several servings per week, of fish highest in mercury [9]) and evidence for subclinical neurologic effects 
detectable  with  specialized  testing  is  inconsistent  [45-49].  Conversely,  more  consistent  evidence 
suggests that fish consumption may favorably affect clinical neurologic events in adults, including 
ischemic stroke [32], cognitive decline and dementia [34], and depression and other neuropsychiatric 
disorders [35,50,51]. Thus, the balance of evidence does not suggest strong harm of fish consumption on 
neurologic outcomes in adults, but rather suggests significant potential benefits.  
The most concerning potential health effects of chronic low-level mercury exposure in adults are on 
CVD  risk  and  outcomes.  In  vitro  and  animal-experimental  studies  [2,3,6,52-61],  as  well  as  some 
observational studies of intermediate risk factors in humans [62-67], suggest that mercury has a variety 
of effects that could increase cardiovascular risk (Table 1).  
 
Table 1. Experimentally-observed effects of mercury which may increase CVD risk. 
Systemic Effects 
 Promotion of free radicals and reactive oxygen species 
 Inhibition of antioxidant systems (glutathione peroxidase, catalase, superoxide dismutase) 
 Increased lipid (e.g., LDL cholesterol) peroxidation 
 Promotion of blood coagulation (clotting) 
 Inhibition of endothelial cell migration 
Direct Cardiovascular Effects 
 Reduction in myocardial contractile force 
 Increased calcium release from myocardial sarcoplasmic reticulum 
 Reduction in left ventricular myosin ATPase activity 
 Decreased heart rate variability and increased blood pressure 
 
While these experimental results and observational studies of intermediate risk factors are suggestive, 
investigation of actual disease endpoints in humans provides the best evidence to confirm potential 
effects of an exposure on chronic disease. Six studies have reported on the relations between mercury 
exposure and CVD endpoints in humans (Table 2) [68-73]. Among men in Kuopio, Finland, those in the 
highest third of hair mercury content (≥ 2.03 ug/g) had 66% higher risk of acute coronary syndromes 
compared to men in the lower third (< 0.84 ug/g) [72]. In two prospective studies in Sweden [68,69], 
higher  blood  mercury  levels  were  not  significantly  associated  with  CVD  risk.  In  a  retrospective 
case-control study in Europe, men in the highest two quintiles of toenail mercury content (median levels 
0.36 and 0.66 ug/g, respectively) had ~2-fold higher risk of nonfatal myocardial infarction, compared to 
men in the lowest fifth (0.11 ug/g) [70]. In a prospective study among U.S. men, toenail mercury 
concentrations were not significantly associated with CHD risk, even in the highest quintile (median 
level 1.34 ug/g) [71]. Finally, in a large prospective study in Sweden, erythrocyte mercury levels were 
not associated with risk of stroke [73].  Int. J. Environ. Res. Public Health 2009, 6                 
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Table 2. Prior studies of mercury and cardiovascular events in humans. 
Author, Year  Design  Country  Exposure  Outcome  No. of 
Cases 
Relative Risk (5% CI) 
with High Mercury * 
Ahlqwist, 1999  Prospective 
cohort 
Sweden  Serum 
mercury 
Total myocardial 
infarction, Stroke 
87, 77  RR = 0.71 (0.40, 1.26)† 
for MI; RR = NS (data 
not reported) for stroke 
Hallgren, 2001  Prospective 
(nested) 
case-control 
Sweden  Erythrocyte 
mercury 
Total myocardial 
infarction 
78  RR = 0.51  
(0.21, 1.24) 
 
Guallar, 2002  Retrospective 
case-control 
8 European 
countries 
and Israel 
Toenail 
mercury 
Nonfatal 
myocardial 
infarction 
684  RR = 2.16 
(1.09, 4.29) 
 
Yoshizawa, 2002  Prospective 
(nested) 
case-control  
USA  Toenail 
mercury 
Total myocardial 
infarction + 
coronary 
revascularization  
470  RR = 1.03 
(0.65, 1.65) 
 
Virtanen, 2005  Prospective 
cohort 
Finland  Hair 
mercury  
Total acute 
coronary events 
282  RR = 1.66 
(1.20, 2.29) 
 
Wennberg, 2007  Prospective 
(nested) 
case-control 
Sweden  Erythrocyte 
mercury 
Stroke  369  RR = 0.99 (0.93, 1.06) 
in men; RR = 1.00 
(0.94, 1.08) in women  
*Multivariable-adjusted relative risk (RR) comparing the highest vs. the lowest category of mercury levels, 
except for Wennberg et al. for which the RR corresponds to each one ng/g increase in erythrocyte mercury. 
†Personal communication (Calle Bengtsson, June 6, 2006). NS = nonsignificant. 
 
Each of these studies had important potential limitations. In the Kuopio study, higher CHD risk was 
not seen until hair mercury levels exceeded ~2.0 ug/g, a level higher than the 95
th percentile of hair 
mercury levels among U.S. women of childbearing age (1.73 ug/g), nearly double the 90
th percentile 
(1.11 ug/g), and more than 10-fold higher than the average population exposure (0.19 ug/g). At hair 
mercury levels below ~2.0 ug/g in the Kuopio study, no significant relationships with CHD risk were 
seen; indeed, for CVD death and CHD death, individuals with hair mercury levels between 0.84 and  
2.03 ug/g had trends toward lower risk than individuals with lower hair mercury levels. In the two 
earliest  Swedish  studies,  relatively  few  events occurred,  limiting  statistical  power.  Ahlqwist  et al. 
assessed mercury exposure in serum, which would reflect inorganic mercury from dental amalgams in 
addition to methylmercury from fish. Guallar et al. was a retrospective study in which only survivors of 
myocardial infarction were included; this could underestimate health benefits of fish consumption due to 
likely stronger benefits for fatal cardiac events (e.g., due to anti-arrhythmic effects), that were not 
included. In addition, more than one-third of eligible controls did not participate in this retrospective 
study,  raising  concerns  for  selection  bias  (i.e.,  the  participating  controls  may  not  have  been 
representative  of  the  study  base  population  giving  rise  to  the  cases).  The  U.S.  cohort  was  large, 
prospective, and utilized toenail mercury, each of which would increase validity of results. Conversely, 
nearly 60 percent of participants were dentists, in whom mercury exposures would include both MeHg Int. J. Environ. Res. Public Health 2009, 6                 
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from  fish  consumption  and  inorganic  mercury  from  working  with  mercury-containing  dental  
amalgams [40]; thus, toenail mercury levels represented the combination of these exposures, which 
might have reduced the ability to detect associations with disease risk due to lower toxicity of inorganic 
mercury, compared with MeHg. When results were limited to the nondentists, trends toward higher 
CHD risk were seen with higher mercury levels, but results were not statistically significant due to fewer 
numbers of subjects in this subset [71].  
Thus, the results of studies of mercury and cardiovascular events have been inconsistent, with only 
six  published  studies  of  this  relationship  and  potential  important  limitations  to  each  study.  A 
meta-analysis  of  the  five  studies  that  evaluated  CHD  events  (Figure  3)  indicated  no  significant 
association between higher mercury exposure and risk of CHD (pooled RR = 1.12, 95% CI = 0.71-1.75) [1]. 
Most of these studies also excluded women, in whom CVD causes more deaths than the next seven 
causes of death combined, and did not evaluate stroke, the second leading cause of CVD morbidity and 
mortality [74]. Thus, the effect of mercury exposure on CVD risk has not been adequately studied, and 
U.S.  regulatory  agencies  have  identified  this  as  a  significant  area  of  uncertainty  requiring  further 
attention [5]. Other quantitative analyses of risks and benefits of fish consumption also concluded that 
the current data is insufficient to quantitate the extent to which mercury affects CVD risk, and that the 
published evidence is also qualitatively ambiguous [75].  
Figure 3. Meta-analysis of studies of mercury exposure and risk of coronary heart disease 
(CHD). Relative risk (■) and 95% CIs (–) are shown comparing the highest to the lowest 
quantile  of  mercury  exposure  after  adjustment  for  other  risk  factors.  Adapted  from 
Mozaffarian and Rimm [1]. 
 
Notably, even if chronic mercury exposure were to increase CVD risk, the most important question 
for an individual decision regarding fish intake would be the tipping point of the relative harm from 
mercury vs. benefit from n-3 PUFA in the fish [76]. In other words, at what concentration of mercury, 
vs. content of n-3 PUFA, might the presence of MeHg change the health effects of fish consumption 
from net benefit to harm? Some data is available to help answer this question. First, in the two studies 
that observed higher  cardiovascular risk with higher vs. lower mercury  levels, the  net relationship 
between overall fish consumption and CHD risk was still protective [70,72,77]. This suggests that, on Int. J. Environ. Res. Public Health 2009, 6                 
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average, fish consumption lowers CVD risk even in populations in which relative adverse effects of 
mercury were identified. Thus, the remaining uncertainty is: does this average beneficial effect of fish 
consumption differ at some level of mercury  exposure? Unfortunately, most prior studies have not 
evaluated this potential interaction. The Kuopio investigators did report the interaction between effects 
of  fish consumption, as reflected by serum  n-3 PUFA  levels, and effects of  mercury exposure, as 
measured in hair [77]. Whether mercury levels were higher or lower, greater n-3 PUFA consumption 
was still associated with lower risk of CHD – higher mercury exposure simply lessened the slope of this 
benefit, but did not cause higher net risk (Figure 4). These findings suggest that, on average, (1) MeHg in 
fish may lessen the benefits of fish intake – a finding that has major implications for regulatory decisions 
regarding control of mercury emissions, because greater public health benefit may be derived from fish 
consumption if mercury levels were decreased; but (2) even consumption of mercury-containing fish 
provides some cardiovascular benefit compared with no fish consumption at all – a finding has major 
implications for an individual’s decision to consume or not consume a particular fish meal that contains 
mercury. Further investigation of this potential interaction, including both higher and lower ranges of 
both n-3 PUFA and mercury exposure, is clearly warranted. 
Figure  4.  The  interaction  between  exposure  to  n-3  PUFA  and  mercury  from  fish 
consumption. Serum docosahexaenoic acid (DHA) and docosopentaenoic acid (DPA) and 
hair mercury were measured in 1,871 participants who were prospectively followed for fatal 
or nonfatal acute coronary heart disease (CHD) [77]. Greater fish consumption (reflected by 
higher serum  n-3 PUFA  levels) was associated with  lower CHD risk whether  mercury 
exposure  was  high  (>  2.0  ug/g,  representing  the  highest  tertile  of  exposure)  or  low  
(< 2.0 ug/g, representing the lowest two tertiles of exposure). However, the slope of this 
benefit was different: the higher relative risk of CHD (RR = 1.66) seen with higher mercury 
exposure in this study reflects, in essence, the difference in slope between these two lines. 
Thus, those with higher mercury exposure had less relative benefit - but not net harm – from 
higher fish consumption. 
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4. Selenium and Cardiovascular Risk 
 
Selenium, an essential dietary trace mineral, is a critical component of numerous selenoproteins in 
humans [78-80]. Food sources include fish and other seafood, red meat, eggs, chicken, and liver [81]. 
Wheat germ, brewer’s yeast, grains, and some vegetables may also be good sources, depending on the 
soil selenium concentration in which these crops were grown, that can vary substantially across different 
geographic regions [78,81]. Selenoproteins are important components of several antioxidant systems 
(e.g., glutathione peroxidase) that actively protect against damage from free radicals and reactive oxygen 
species [79,80]. Experimental studies suggest that these selenium systems may reduce CVD risk via 
several mechanisms (Table 3) [82-89]. For example, antioxidant defenses may reduce vascular and 
tissue  injury  resulting  from  formation  of  reactive  oxygen  species  due  to  shear  stress,  hypoxia, 
hypertension,  hyperlipidemia,  and  diabetes  [82].  Selenium-related  systems  may  also  decrease  the 
oxidation of lipids and protect the vascular endothelium from damage due to oxidized LDL cholesterol 
particles  [83,84].  Selenium  compounds  may  also  more  directly  influence  myocardial  function  and 
response  to  injury.  In  animal  studies,  selenium  consumption  increases  cardiomyocyte  glutathione 
peroxidase activity [85-87], improves cardiac recovery from ischemia-reperfusion injury [86], limits 
ischemia-induced structural alterations of mitochondria and sarcomeres [86], and reduces myocardial 
infarct size [87]. In diabetic animals, selenium improves cardiac mechanical and electrical dysfunction 
by restoring the cardiomyocyte glutathione redox cycle and restoring altered potassium currents [88]. 
Selenium also prevents myocyte structural abnormalities induced by diabetes, such as myofibril loss, 
reduction in myocyte diameter, and myofilament degeneration [89]. Selenium-intake also markedly 
reduces the incidence of ischemia-induced ventricular arrhythmias in rats [85].  
 
Table 3. Experimentally-observed effects of selenium which may reduce CVD risk. 
Systemic Effects 
 Antioxidant defense against free radicals and reactive oxygen species 
 Decreased lipid peroxidation  
 Protection against vascular damage from oxidized LDL cholesterol particles 
 Antithrombotic effects from decreased plasma thromboxane A2 
Direct Cardiovascular Effects 
 Increased myocardial antioxidant glutathione peroxidase activity 
 Improved cardiac recovery from ischemia-reperfusion injury 
 Limitation of ischemia-induced and diabetes-induced ultrastructural damage 
 Reduction in myocardial infarct size 
 Restoration of altered myocyte ion currents 
 Reduced incidence of ischemia-induced ventricular arrhythmias 
 
As  for  n-3  PUFA  and  mercury,  these  experimental  effects  on  intermediate  risk  factors  require 
confirmation in studies of actual disease endpoints in humans. Variability of selenium content of foods 
from different regions renders selenium consumption difficult to estimate from dietary questionnaires, Int. J. Environ. Res. Public Health 2009, 6                 
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and thus measured biomarkers are optimal to allow valid and reproducible assessment of selenium 
intake. Selenium  levels  in  blood or toenails provide reasonable ranking of differences  in selenium 
consumption in a population [90]. For example, toenail selenium levels are higher with greater dietary 
selenium intake, assess average consumption over the prior 6 to 12 months, and are reproducible over 
time (r = 0.48 for toenail samples obtained six years apart)
 [42,90].
 Toenail selenium levels are also 
higher among selenium supplement users, correlate in a dose-response fashion with supplement dose, 
and are consistent with the geographic distribution of selenium in forage crops [91].  
Several studies have evaluated the relationship between selenium status and CVD endpoints, with 
inconsistent results. These studies have varied widely in terms of population studied, assessment of 
selenium exposure (e.g., blood, toenail, supplements), outcomes examined (e.g., CHD mortality, acute 
MI, combined CVD endpoints), and study size (ranging from 6 to 683 cases) [92]. In a prospective study 
among generally healthy U.S. men, no significant association was present between toenail selenium 
levels and total CHD events during five years follow-up (comparing extreme quintiles of selenium, the 
multivariate-adjusted RR was 0.86, 95% CI = 0.55-1.32, p trend = 0.75), but higher selenium levels were 
associated with a trend toward lower risk of nonfatal heart attacks (RR = 0.54, 95% CI = 0.31-0.93;  
p trend = 0.07) [93]. Retrospective case-control studies have generally seen stronger inverse associations 
between selenium levels and CVD risk than prospective studies that would be less susceptible to control 
selection bias. In addition to selection bias, possible limitations of some of these individual studies 
include low statistical power due to few numbers of events, or evaluation of combined endpoints, e.g., 
including  elective  coronary  revascularization  procedures  as  outcomes.  A  meta-analysis  of  25 
observational studies that measured blood or toenail selenium concentrations and six randomized trials 
that  evaluated  selenium  supplements  demonstrated  a  pooled  relative  risk  for  CHD  of  0.43  
(95% CI = 0.29-0.66) in case-control studies and 0.85 (95% CI = 0.74-0.99) in cohort studies, comparing 
the  highest  with  the  lowest  selenium  concentration  categories,  and  0.89  (95%  CI  =  0.68-1.17) in 
randomized trials, comparing supplement users to nonusers [92]. The effect of selenium consumption on 
CVD risk may also be modified by duration of consumption, smoking, alcohol use, or antioxidant 
vitamin  intake,  the  influences  of  which  were  not  evaluated  in  most  prior  studies.  Thus,  while 
animal-experiments suggest that selenium may protect against CVD, an American Heart Association 
Science Advisory in 1999 concluded that “little information is available on the preventive effects of 
[selenium] in human populations [94].”  
Selenium intake is thought to be adequate in many populations [95], which may limit detection of 
relations between selenium intake and disease risk. However, the threshold for adequate selenium intake 
is based on prevention of Keshan disease (a rare cardiomyopathy) and on secondary functional measures 
(such  as  glutathione  peroxidase  activity)  [96].  The  threshold  -  if  any  -  for  prevention  of  CVD  is 
unknown. As described above, in one study among U.S. men, selenium levels were associated with a 
trend  toward  lower  risk  of  nonfatal  heart  attacks  [93],  suggesting  that  selenium  may  influence 
cardiovascular risk even in populations with supposedly adequate intake. Nevertheless, overall, the 
associations of selenium intake with CVD risk, nor any potential thresholds of effect, are currently not 
well-established.  
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5. Interaction between Mercury, Selenium and Cardiovascular Risk 
 
While the relations of mercury and selenium with cardiovascular risk are controversial, perhaps the 
most interesting possibility is that these relations are not independent. It has long been hypothesized that 
selenium may protect against toxic effects of mercury, particularly organic MeHg [97-102]. Evidence 
from both in vitro studies and experiments in animals supports this concept [97-110]. Selenium protects 
against  mercury  toxicity  in  rats  [100],  mice  [105],  and  quail  [103],  and  against  mercury-induced 
apoptosis in human cell lines [108]. Cardiovascular protection may be related to antioxidant effects of 
selenoprotein systems, which could minimize damage from mercury-induced free radicals [100]. In rats, 
the mercury-induced reductions in plasma and liver glutathione S-transferase activity can be alleviated 
by co-administration of selenium [107]. Such protection could also result from direct effects of selenium 
on  mercury  kinetics  and  metabolism.  Reduced  selenite  (for  example,  from  glutathione  peroxidase 
activity)  degrades  MeHg  to  less  toxic  inorganic  mercury  [104].  Additionally,  glutathione-reduced 
selenite (selenide) binds with mercury and plasma selenoprotein P to form a ternary complex [109], 
although the biologic significance of this is unclear. Interestingly, in a small randomized trial among 
human subjects with low selenium intake (n = 23), selenium supplementation reduced hair mercury 
levels by one-third over four months [110].  
Epidemiologic  studies  indirectly  support  a  possible  protective  effect  of  selenium  intake  on 
cardiovascular toxicity of mercury [111]. Mercury exposure has been associated with cardiovascular 
risk in European populations with possibly low selenium intake [70,72], but not in a U.S. population 
with likely higher selenium intake [71]. However, in the only prospective study that directly evaluated 
this potential interaction, selenium levels did not significantly modify relations between mercury and 
CHD events [71], although statistical power may have been inadequate to detect an interaction. 
Thus, in vitro studies and animal-experiments suggest that selenium may protect against mercury 
toxicity, but it is unclear whether these findings are relevant to selenium intake and mercury exposure in 
humans. Understanding whether selenium intake prevents the potential CVD toxicity of mercury is 
important both for determining the appropriate level of public health concern for mercury exposure from 
fish consumption in different populations and for making recommendations regarding optimal selenium 
intake  in  the  U.S.  and  other  countries.  Unfortunately,  the  possible  interaction  between  mercury, 
selenium, and cardiovascular risk has not been studied adequately to draw any firm conclusions.  
 
6. Polychlorinated Biphenyls (PCBs) and Dioxins 
 
Although the focus of this review is on n-3 PUFA, mercury, and selenium, the potential health effects 
of PCBs and dioxins present in some fish species merit consideration. Exposure to these contaminants 
has been declining steadily since the 1970s [112], when changes in regulatory policies and industry 
practices reduced production and emission levels, lowering levels in foods. Nevertheless, they persist in 
the environment and human tissues for a long time, and attention on their levels in fish species was 
rekindled following publication of a comprehensive analysis that farmed salmon contained higher levels 
of PCBs/dioxins than wild salmon [113], a result that received considerable media attention. Placed in 
perspective, however, the average levels in farmed salmon were low, only ~2% of the FDA action level. 
Thus, the main finding was not that average levels of PCBs/dioxins in farmed salmon were high, but Int. J. Environ. Res. Public Health 2009, 6                 
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simply that average levels in wild salmon were even lower. Most importantly, when the potential cancer 
risks of the PCBs/dioxins in both farmed and wild salmon were quantitatively compared to the expected 
CHD benefits from the n-3 PUFA, the estimated magnitudes of the hypothesized cancer risk were orders 
of magnitude lower than the reduction in cardiac mortality (Figure 5) [114]. Three additional points 
deserve attention. First, the estimates of cancer risk were based on 70-year lifetimes of eating salmon at 
levels to achieve 1000 mg/d EPA+DHA, or approximately seven 3.5-oz wild salmon servings/week or 
three 3.5-oz farmed salmon servings/week for 70 years. However, based on the nonlinear relationship 
between EPA+DHA intake and CHD mortality [1], a similar CHD mortality reduction would likely 
occur at one-fourth of the consumption level (i.e., 250 mg/d EPA+DHA), but with only one-fourth of the 
cancer  risk  (i.e.,  6  or  2  excess  cancer  deaths  per  100,000  lifetimes  for  farmed  or  wild  salmon, 
respectively). Second, the estimated cancer risks of PCBs/dioxins include a 10-fold uncertainty factor; 
i.e., the true effects at these consumption levels may be 1/10 as large, or 0.6 or 0.2 excess cancer deaths 
per 100,000 lifetimes for farmed or wild salmon, respectively. Finally, the estimated cancer risks of 
PCBs/dioxins are largely derived from extrapolation of results from limited high human exposures and 
animal-experiments, whereas the calculated benefits for CHD death are derived from multiple large 
prospective cohort studies and randomized controlled clinical trials in humans of fish and n-3 PUFA 
consumption and actual CHD mortality [1,114]. Thus, whether the true excess cancer risk for 70-years 
consumption of farmed or wild salmon would be 24 or 8, 6 or 2, or 0.6 or 0.2 deaths per 100,000 
lifetimes, these risks pale in comparison, both in magnitude and strength of evidence, to the many 
thousands  of  CHD  deaths  that  would  be  prevented  by  such  consumption.  Because  levels  of 
PCBs/dioxins may be higher in some freshwater fish species caught in certain local rivers or lakes, sports 
fishermen  who  regularly  consume  locally  caught  freshwater  fish  should  consult  local  advisories. 
However,  for  commercially  purchased  fish  and  shellfish,  based  on  the  relatively  low  contents  of 
PCBs/dioxins [1], the greater strength and quality of evidence for CHD benefits of n-3 PUFA vs. cancer 
risks of PCBs/dioxins, and the quantitatively far larger CHD benefits compared with the hypothesized 
cancer risks, the great majority of individuals who consume commercially purchased fish should not be 
concerned about PCB or dioxin content in making fish consumption decisions; indeed, such concern 
may substantially increase health risk by leading to reduced fish consumption. Continued attention to 
reducing  PCB  and  dioxin  emissions  into  the  environment  is  important,  but  in  contrast  to  MeHg 
exposure, this is not a seafood-specific issue: the majority (> 90%) of PCBs and dioxins in the food 
supply  are  consumed  from  non-seafood  sources,  in  particular  meats,  dairy  products,  and  
vegetables [115,116].  
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Figure 5. Calculated cancer risks vs. cardiac benefits from a lifetime of regular consumption 
of farmed or wild salmon, based on contents of PCBs/dioxins and n-3 PUFA in farmed and 
wild salmon [114]. The estimated cancer risks - 24 vs. 8 deaths for farmed vs. wild salmon, 
respectively – are orders of magnitude smaller than the calculated cardiac benefits of 7,125 
fewer cardiac deaths for either farmed or wild salmon consumption. 
 
 
7. Conclusions 
 
Consistent  evidence  from  human  experimental  studies,  case-control  studies,  prospective  cohort 
studies, and randomized controlled trials indicates that modest consumption of fish significantly reduces 
cardiac  death.  The  magnitude  of  benefit  is  substantial,  with  36%  lower  risk  with  consumption  of  
250 mg/d EPA+DHA (equivalent to ~1-2 servings of fatty fish per week), compared with no intake. The 
strength, quality, and consistency of evidence for health effects of chronic low-level mercury exposure 
in adults are much less robust, indicating a need for further investigation of possible effects of such 
exposure on disease outcomes in appropriately powered prospective human studies. The conflicting 
results of prior studies of mercury and CVD risk are not dose-related, as some studies with relatively low 
exposures observed a positive association, whereas other studies found no significant associations at 
similar or higher exposures. Notably, even in the two studies that observed a positive relationship 
between mercury exposure and cardiovascular risk, the overall average effect of fish consumption was 
protective: mercury exposure appeared to lessen, but not reverse, the cardiovascular protection of fish 
intake. Animal-experiments suggest that selenium may protect against CVD, but studies of selenium 
intake and cardiovascular endpoints in humans are inconsistent, and a possible interaction between 
mercury and selenium for CVD risk has not been adequately studied in humans. Based on the current 
evidence, the health risks for adults of not consuming fish outweigh potential risks from mercury or 
other contaminants. Modest consumption (1-2 fish servings per week) appears to provide most of the 
reduction in CHD mortality, and concerns over possible accompanying effects of mercury or other 
contaminants in adults can be curtailed by simply choosing a variety of different fish and seafood [1,11].  Int. J. Environ. Res. Public Health 2009, 6                 
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Several unanswered questions remain. First, growing evidence suggests that fish consumption has 
benefits  for  health  outcomes  beyond  CHD  mortality,  including  nonfatal  cardiovascular  events  and 
several noncardiovascular outcomes: these potential effects, and their dose-responses, require further 
investigation. Second, whereas current evidence does not support a need for any advisory to limit intake 
of fish or specific fish species for health effects in adults, further research is needed to elucidate the 
potential health effects of mercury exposure and the level, if any, at which potential effects of mercury 
could equal or outweigh the benefits from n-3 PUFA consumption. Even if further research ultimately 
confirms that, as suggested by current evidence, the net health effect of any single fish meal is nearly 
always beneficial, the extent to which mercury might reduce this net benefit must be evaluated to inform 
regulatory decisions regarding control of mercury emissions, in that greater public health benefit may be 
derived  from  fish  consumption  if  mercury  levels  were  decreased  further. Third,  whether  selenium 
protects against CVD risk and/or against potential toxic effects of mercury, as well as any threshold of 
such effects, must be better established. Finally, although not a focus of this present review, both the 
intended and unanticipated consequences of government advisories, public health recommendations, 
and  media reports regarding health effects of fish consumption  must be better understood, so that 
well-intentioned messages do not cause confusion or ultimate harm. The answers to these questions will 
have significant implications for our understanding of how n-3 PUFA, mercury, and selenium influence 
health risk and will clarify the most appropriate emphases for recommendations regarding fish intake to 
improve health in adults. As future studies are completed, continued careful consideration of the strength 
and consistency of the evidence, as well as the relative magnitudes of effect, is imperative. 
 
Acknowledgments 
 
I am grateful for past reviews by Dr. Rafael Diaz-Flores and Dr. Hooman Hajian on environmental 
sources and experimental effects of mercury  and selenium. I thank Dr. Eric Rimm  and Dr. David 
Siscovick for their friendship, support, and elucidating conversations and collaborations.  
Supported by the Searle Scholar Award from the Searle Funds at The Chicago Community Trust. The 
funding source had no role in study design; in the collection, analysis, or interpretation of data; in the 
writing of the report; or in the decision to submit the paper for publication. 
Disclosures: Research grants (significant) from NHLBI and NIEHS (K08 HL 075628-01, R01 HL 
085710-01, R01 ES 014433-01A2); the Searle Scholar Award from the Searle Funds at The Chicago 
Community Trust; the Genes and Environment Initiative at the Harvard School of Public Health; the 
Gates Foundation/World Health Organization Global Burden of Diseases, Injuries, and Risk Factors 
Study;  and  GSK,  Sigma  Tau,  and  Pronova  for an  investigator-initiated trial  of  fish  oil  to  prevent 
post-surgical arrhythmia. Honoraria (modest) for speaking at scientific conferences and reviewing on 
topics related to diet and cardiovascular disease, including from the U.S. Food and Drug Administration, 
United Nations, World Health Organization, UpToDate, International Life Sciences Institute, Aramark, 
and several universities and scientific organizations. No ownership, patents, stocks, advisory board 
membership, nor speaking board membership. 
 Int. J. Environ. Res. Public Health 2009, 6                 
 
1909 
References 
 
1.  Mozaffarian, D.; Rimm, E.B. Fish intake, contaminants, and human health: evaluating the risks 
and the benefits. JAMA 2006, 296, 1885-1899. 
2.  Mahaffey, K.R. Methylmercury: a new look at the risks. Public Health Rep. 1999, 114, 396-399, 
402-413. 
3.  Committee on the Toxicological Effects of Methylmercury; Board on Environmental Studies and 
Toxicology; Commission on Life Sciences; National Research Council. Toxicological Effects of 
Methylmercury; National Academy Press: Washington, DC, USA, 2000. 
4.  Rice, D.C.; Schoeny, R.; Mahaffey, K. Methods and rationale for derivation of a reference dose for 
methylmercury by the U.S. EPA. Risk Anal. 2003, 23, 107-115. 
5.  Rice, D.C. The US EPA reference dose for methylmercury: sources of uncertainty. Environ. Res. 
2004, 95, 406-413. 
6.  Chan, H.M.; Egeland, G.M. Fish consumption, mercury exposure, and heart diseases. Nutr. Rev. 
2004, 62, 68-72. 
7.  U.S. Environmental Protection Agency. Mercury Study Report to Congress. Available online: 
http://www.epa.gov/mercury/report.htm (accessed January 24, 2006). 
8.  Gochfeld, M. Cases of mercury exposure, bioavailability, and absorption. Ecotoxicol. Environ. 
Saf. 2003, 56, 174-179. 
9.  Risher, J.F. Too much of a good thing (fish): methylmercury case study. J. Environ. Health 2004, 
67, 9-14, 28. 
10.  Mozaffarian, D. Does alpha-linolenic acid intake reduce the risk of coronary heart disease? A 
review of the evidence. Altern. Ther. Health Med. 2005, 11, 24-30. 
11.  Institute of Medicine of the National Acadamies. Seafood Choices: Balancing Benefits and Risks. 
2006. Available online: http://www.iom.edu/CMS/3788/23788/37679.aspx (accessed January 18, 
2008). 
12.  U.S. Department of Health and Human Services; U.S. Food and Drug Administration. What You 
Need to Know About Mercury in Fish and Shellfish: 2004 EPA and FDA Advice for women who 
might become pregnant, women who are pregnant, nursing mothers, young children. Available 
online: http://www.cfsan.fda.gov/~dms/admehg3.html (accessed January 14, 2008). 
13.  Leaf, A.; Kang, J.X.; Xiao, Y.F.; Billman, G.E. Clinical prevention of sudden cardiac death by n-3 
polyunsaturated  fatty  acids  and  mechanism  of  prevention  of  arrhythmias  by  n-3  fish  oils. 
Circulation 2003, 107, 2646-2652. 
14.  McLennan, P.L. Myocardial membrane fatty acids and the antiarrhythmic actions of dietary fish 
oil in animal models. Lipids 2001, 36, S111-114. 
15.  Charnock, J.S.; McLennan, P.L.; Abeywardena, M.Y. Dietary modulation of lipid metabolism and 
mechanical performance of the heart. Mol. Cell Biochem. 1992, 116, 19-25. 
16.  Kenny, D.; Warltier, D.C.; Pleuss, J.A.; Hoffmann, R.G.; Goodfriend, T.L.; Egan, B.M. Effect of 
omega-3 fatty acids on the vascular response to angiotensin in normotensive men. Am. J. Cardiol. 
1992, 70, 1347-1352. 
17.  Chin,  J.P.;  Gust,  A.P.;  Nestel,  P.J.;  Dart,  A.M.  Marine  oils  dose-dependently  inhibit 
vasoconstriction of forearm resistance vessels in humans. Hypertension 1993, 21, 22-28. Int. J. Environ. Res. Public Health 2009, 6                 
 
1910 
18.  Geleijnse, J.M.; Giltay, E.J.; Grobbee, D.E.; Donders, A.R.; Kok, F.J. Blood pressure response to 
fish oil supplementation: metaregression analysis of randomized trials. J. Hypertens. 2002, 20, 
1493-1499. 
19.  Mozaffarian, D.; Geelen, A.; Brouwer, I.A.; Geleijnse, J.M.; Zock, P.L.; Katan, M.B. Effect of fish 
oil on heart rate in humans: A meta-analysis of randomized controlled trials. Circulation 2005, 
112, 1945-1952. 
20.  Mozaffarian, D.; Gottdiener, J.S.; Siscovick, D.S. Intake of tuna or other broiled or baked fish vs. 
fried fish and cardiac structure, function, and hemodynamics. Am. J. Cardiol. 2006, 97, 216-222. 
21.  Nestel, P.J. Fish oil and cardiovascular disease: lipids and arterial function. Am. J. Clin. Nutr. 
2000, 71, 228S-231S. 
22.  Christensen, J.H. n-3 fatty acids and the risk of sudden cardiac death. Emphasis on heart rate 
variability. Dan. Med. Bull. 2003, 50, 347-367. 
23.  Mori, T.A.; Beilin, L.J. Omega-3 fatty acids and inflammation. Curr. Atheroscler. Rep. 2004, 6, 
461-467. 
24.  Kristensen,  S.D.;  Iversen,  A.M.;  Schmidt,  E.B. n-3  polyunsaturated  fatty  acids  and  coronary 
thrombosis. Lipids 2001, 36 Suppl, S79-82. 
25.  Clandinin, M.T.; Cheema, S.; Field, C.J.; Garg, M.L.; Venkatraman, J.; Clandinin, T.R. Dietary 
fat:  exogenous  determination  of  membrane  structure  and  cell  function.  Faseb.  J.  1991,  5, 
2761-2769. 
26.  Feller,  S.E.;  Gawrisch,  K.  Properties  of  docosahexaenoic-acid-containing  lipids  and  their 
influence on the function of rhodopsin. Curr. Opin. Struct. Biol. 2005, 15, 416-422. 
27.  Vanden Heuvel, J.P. Diet, fatty acids, and regulation of genes important for heart disease. Curr. 
Atheroscler. Rep. 2004, 6, 432-440. 
28.  Oomen, C.M.; Feskens, E.J.; Rasanen, L.; Fidanza, F.; Nissinen, A.M.; Menotti, A.; Kok, F.J.; 
Kromhout, D. Fish consumption and coronary heart disease mortality in Finland, Italy, and The 
Netherlands. Am. J. Epidemiol. 2000, 151, 999-1006. 
29.  Mozaffarian, D.; Lemaitre, R.N.; Kuller, L.H.; Burke, G.L.; Tracy, R.P.; Siscovick, D.S. Cardiac 
benefits of fish consumption may depend on the type of fish meal consumed: the Cardiovascular 
Health Study. Circulation 2003, 107, 1372-1377. 
30.  Harris, W.S.; Mozaffarian, D.; Lefevre, M.; Toner, C.D.; Colombo, J.; Cunnane, S.C.; Holden, 
J.M.; Klurfeld, D.M.; Morris, M.C.; Whelan, J. Towards establishing dietary reference intakes for 
eicosapentaenoic and docosahexaenoic acids. J. Nutr. 2009, 139, 804S-819S. 
31.  Sun, Q.; Ma, J.; Campos, H.; Rexrode, K.M.; Albert, C.M.; Mozaffarian, D.; Hu, F.B. Blood 
concentrations of individual long-chain n-3 fatty acids and risk of nonfatal myocardial infarction. 
Am. J. Clin. Nutr. 2008, 88, 216-223. 
32.  He, K.; Song, Y.; Daviglus, M.L.; Liu, K.; Van Horn, L.; Dyer, A.R.; Goldbourt, U.; Greenland, P. 
Fish consumption and incidence of stroke: a meta-analysis of cohort studies. Stroke 2004, 35, 
1538-1542. 
33.  Mozaffarian, D.; Psaty, B.M.; Rimm, E.B.; Lemaitre, R.N.; Burke, G.L.; Lyles, M.F.; Lefkowitz, 
D.; Siscovick, D.S. Fish  intake and risk of  incident atrial  fibrillation. Circulation 2004, 110, 
368-373. Int. J. Environ. Res. Public Health 2009, 6                 
 
1911 
34.  Morris, M.C.; Evans, D.A.; Tangney, C.C.; Bienias, J.L.; Wilson, R.S. Fish consumption and 
cognitive decline with age in a large community study. Arch. Neurol. 2005, 62, 1849-1853. 
35.  Lin,  P.Y.;  Su,  K.P.  A  meta-analytic  review  of  double-blind,  placebo-controlled  trials  of 
antidepressant efficacy of omega-3 fatty acids. J. Clin. Psychiatry 2007, 68, 1056-1061. 
36.  U.S.  Food  and  Drug  Administration.  Mercury  in fish:  Cause for  concern?  Available  online: 
http://www.fda.gov/fdac/reprints/mercury.html (accessed January 14, 2008). 
37.  The  Risk  Assessment  Information  System.  Toxicity  Summary  for  Mercury.  Available  online: 
http://risk.lsd.ornl.gov/tox/profiles/mercury_f_V1.shtml (accessed January 14, 2008). 
38.  U.S. Geological Survey. Mercury in the Environment. Available online: http://www.usgs.gov/ 
themes/factsheet/146-00/ (accessed October 25, 2005). 
39.  Hightower,  J.M.;  Moore,  D.  Mercury  levels  in  high-end  consumers  of  fish.  Environ.  Health 
Perspect 2003, 111, 604-608. 
40.  Joshi, A.; Douglass, C.W.; Kim, H.D.; Joshipura, K.J.; Park, M.C.; Rimm, E.B.; Carino, M.J.; 
Garcia,  R.I.;  Morris,  J.S.;  Willett,  W.C.  The  relationship  between  amalgam  restorations  and 
mercury levels in male dentists and nondental health professionals. J. Public Health Dent. 2003, 
63, 52-60. 
41.  MacIntosh, D.L.; Williams, P.L.; Hunter, D.J.; Sampson, L.A.; Morris, S.C.; Willett, W.C.; Rimm, 
E.B. Evaluation of a  food frequency questionnaire-food composition approach  for estimating 
dietary intake of inorganic arsenic and methylmercury. Cancer Epidemiol. Biomarkers Prev. 1997, 
6, 1043-1050. 
42.  Garland, M.; Morris, J.S.; Rosner, B.A.; Stampfer, M.J.; Spate, V.L.; Baskett, C.J.; Willett, W.C.; 
Hunter, D.J. Toenail trace element levels as biomarkers: reproducibility over a 6-year period. 
Cancer Epidemiol. Biomarkers Prev. 1993, 2, 493-497. 
43.  Rosner,  B.;  Hennekens,  C.H.;  Kass,  E.H.;  Miall,  W.E.  Age-specific  correlation  analysis  of 
longitudinal blood pressure data. Am. J. Epidemiol. 1977, 106, 306-313. 
44.  Berglund, M.; Lind, B.; Bjornberg, K.A.; Palm, B.; Einarsson, O.; Vahter, M. Inter-individual 
variations of human mercury exposure biomarkers: a cross-sectional assessment. Environ. Health 
2005, 4, 20. 
45.  Lebel, J.; Mergler, D.; Branches, F.; Lucotte, M.; Amorim, M.; Larribe, F.; Dolbec, J. Neurotoxic 
effects of low-level methylmercury contamination in the Amazonian Basin. Environ. Res. 1998, 
79, 20-32. 
46.  Yokoo, E.M.;  Valente,  J.G.;  Grattan,  L.; Schmidt,  S.L.;  Platt,  I.;  Silbergeld,  E.K.  Low  level 
methylmercury exposure affects neuropsychological function in adults.  Environ. Health 2003,  
2, 8. 
47.  Auger, N.; Kofman, O.; Kosatsky, T.; Armstrong, B. Low-level methylmercury exposure as a risk 
factor for neurologic abnormalities in adults. Neurotoxicology 2005, 26, 149-157. 
48.  Weil, M.; Bressler, J.; Parsons, P.; Bolla, K.; Glass, T.; Schwartz, B. Blood mercury levels and 
neurobehavioral function. JAMA 2005, 293, 1875-1882. 
49.  Johansson,  N.;  Basun,  H.;  Winblad,  B.;  Nordberg,  M.  Relationship  between  mercury 
concentration in blood, cognitive performance, and blood pressure, in an elderly urban population. 
Biometals 2002, 15, 189-195. Int. J. Environ. Res. Public Health 2009, 6                 
 
1912 
50.  Peet, M.; Stokes, C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs 2005, 65, 
1051-1059. 
51.  Young, G.; Conquer, J. Omega-3 fatty acids and neuropsychiatric disorders. Reprod Nutr. Dev. 
2005, 45, 1-28. 
52.  Wakita, Y. Hypertension induced by methyl mercury in rats. Toxicol. Appl. Pharmacol. 1987, 89, 
144-147. 
53.  Kostka, B.; Michalska, M.; Krajewska, U.; Wierzbicki, R. Blood coagulation changes in rats 
poisoned with methylmercuric chloride (MeHg). Pol. J. Pharmacol. Pharm. 1989, 41, 183-189. 
54.  Halbach, S. Mercury compounds: lipophilicity and toxic effects on isolated myocardial tissue. 
Arch. Toxicol. 1990, 64, 315-319. 
55.  Rungby, J.; Ernst, E. Experimentally  induced  lipid peroxidation after exposure to chromium, 
mercury or silver: interactions with carbon tetrachloride. Pharmacol. Toxicol. 1992, 70, 205-207. 
56.  Jansson,  G.;  Harms-Ringdahl,  M.  Stimulating  effects  of  mercuric-  and  silver  ions  on  the 
superoxide anion production in human polymorphonuclear leukocytes. Free Radic. Res. Commun. 
1993, 18, 87-98. 
57.  Oliveira, E.M.; Vassallo, D.V.; Sarkis, J.J.; Mill, J.G. Mercury effects on the contractile activity of 
isolated heart muscle. Toxicol. Appl. Pharmacol. 1994, 128, 86-91. 
58.  InSug, O.; Datar, S.; Koch, C.J.; Shapiro, I.M.; Shenker, B.J. Mercuric compounds inhibit human 
monocyte function by inducing apoptosis: evidence for formation of reactive oxygen species, 
development of mitochondrial membrane permeability transition and loss of reductive reserve. 
Toxicology 1997, 124, 211-224. 
59.  da Cunha, V.; Souza, H.P.; Rossoni, L.V.; Franca, A.S.; Vassallo, D.V. Effects of mercury on the 
isolated  perfused  rat  tail  vascular  bed  are  endothelium-dependent.  Arch.  Environ.  Contam. 
Toxicol. 2000, 39, 124-130. 
60.  de Assis, G.P.; Silva, C.E.; Stefanon, I.; Vassallo, D.V. Effects of small concentrations of mercury 
on the contractile activity of the rat ventricular myocardium. Comp. Biochem. Physiol. C Toxicol. 
Pharmacol. 2003, 134, 375-383. 
61.  Moreira, C.M.; Oliveira, E.M.; Bonan, C.D.; Sarkis, J.J.; Vassallo, D.V. Effects of mercury on 
myosin ATPase in the ventricular myocardium of the rat. Comp. Biochem. Physiol. C Toxicol. 
Pharmacol. 2003, 135C, 269-275. 
62.  Sorensen, N.; Murata, K.; Budtz-Jorgensen, E.; Weihe, P.; Grandjean, P. Prenatal methylmercury 
exposure as a cardiovascular risk factor at seven years of age. Epidemiology 1999, 10, 370-375. 
63.  Grandjean,  P.;  Murata,  K.;  Budtz-Jorgensen,  E.;  Weihe,  P.  Cardiac  autonomic  activity  in 
methylmercury neurotoxicity: 14-year follow-up of a Faroese birth cohort. J Pediatr 2004, 144, 
169-176. 
64.  Thurston, S.W.; Bovet, P.; Myers, G.J.; Davidson, P.W.; Georger, L.A.; Shamlaye, C.; Clarkson, 
T.W. Does prenatal  methylmercury exposure  from  fish consumption affect blood pressure  in 
childhood? Neurotoxicology 2007, 28, 924-930. 
65.  Fillion,  M.;  Mergler,  D.;  Sousa  Passos,  C.J.;  Larribe,  F.;  Lemire,  M.;  Guimaraes,  J.R.  A 
preliminary study of mercury exposure and blood pressure in the Brazilian Amazon. Environ. 
Health 2006, 5, 29. Int. J. Environ. Res. Public Health 2009, 6                 
 
1913 
66.  Valera,  B.;  Dewailly,  E.;  Poirier,  P.  Cardiac  autonomic  activity  and  blood  pressure  among 
Nunavik Inuit adults exposed to environmental mercury: a cross-sectional study. Environ. Health 
2008, 7, 29. 
67.  Choi, A.L.; Weihe, P.; Budtz-Jorgensen, E.; Jorgensen, P.J.; Salonen, J.T.; Tuomainen, T.P.; 
Murata, K.; Nielsen, H.P.; Petersen, M.S.; Askham, J.; Grandjean, P. Methylmercury exposure and 
adverse cardiovascular effects  in Faroese whaling men.  Environ. Health Perspect 2009, 117, 
367-372. 
68.  Ahlqwist,  M.;  Bengtsson,  C.;  Lapidus,  L.;  Gergdahl,  I.A.;  Schutz,  A.  Serum  mercury 
concentration  in  relation  to  survival,  symptoms,  and  diseases:  results  from  the  prospective 
population study of women in Gothenburg, Sweden. Acta Odontol Scand 1999, 57, 168-174. 
69.  Hallgren,  C.G.;  Hallmans,  G.;  Jansson,  J.H.;  Marklund,  S.L.;  Huhtasaari,  F.;  Schutz,  A.; 
Stromberg, U.; Vessby, B.; Skerfving, S. Markers of high fish intake are associated with decreased 
risk of a first myocardial infarction. Br. J. Nutr. 2001, 86, 397-404. 
70.  Guallar, E.; Sanz-Gallardo, M.I.; van't Veer, P.; Bode, P.; Aro, A.; Gomez-Aracena, J.; Kark, J.D.; 
Riemersma, R.A.; Martin-Moreno, J.M.; Kok, F.J. Mercury, fish oils, and the risk of myocardial 
infarction. N. Engl. J. Med. 2002, 347, 1747-1754. 
71.  Yoshizawa, K.; Rimm, E.B.; Morris, J.S.; Spate, V.L.; Hsieh, C.C.; Spiegelman, D.; Stampfer, 
M.J.; Willett, W.C. Mercury and the risk of coronary heart disease in men. N. Engl. J. Med. 2002, 
347, 1755-1760. 
72.  Virtanen, J.K.; Voutilainen, S.; Rissanen, T.H.; Mursu, J.; Tuomainen, T.P.; Korhonen, M.J.; 
Valkonen, V.P.; Seppanen, K.; Laukkanen, J.A.; Salonen, J.T. Mercury, fish oils, and risk of acute 
coronary events and cardiovascular disease, coronary heart disease, and all-cause mortality in men 
in eastern Finland. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 228-233. 
73.  Wennberg, M.; Bergdahl, I.A.; Stegmayr, B.; Hallmans, G.; Lundh, T.; Skerfving, S.; Stromberg, 
U.; Vessby, B.; Jansson, J.H. Fish intake, mercury, long-chain n-3 polyunsaturated fatty acids and 
risk of stroke in northern Sweden. Br. J. Nutr. 2007, 98, 1038-1045. 
74.  Thom, T.; Haase, N.; Rosamond, W.; Howard, V.J.; Rumsfeld, J.; Manolio, T.; Zheng, Z.J.; Flegal, 
K.; O'Donnell, C.; Kittner, S.; Lloyd-Jones, D.; Goff, D.C., Jr.; Hong, Y.; Adams, R.; Friday, G.; 
Furie,  K.;  Gorelick,  P.;  Kissela,  B.;  Marler,  J.;  Meigs,  J.;  Roger,  V.;  Sidney,  S.;  Sorlie,  P.; 
Steinberger,  J.;  Wasserthiel-Smoller,  S.;  Wilson,  M.;  Wolf,  P.  Heart  disease  and  stroke 
statistics-2006 update: a report from the American Heart Association Statistics Committee and 
Stroke Statistics Subcommittee. Circulation 2006, 113, e85-151. 
75.  Konig, A.; Bouzan, C.; Cohen, J.T.; Connor, W.E.; Kris-Etherton, P.M.; Gray, G.M.; Lawrence, 
R.S.; Savitz, D.A.; Teutsch, S.M. A quantitative analysis of fish consumption and coronary heart 
disease mortality. Am. J. Prev. Med. 2005, 29, 335-346. 
76.  Mozaffarian, D.; Rimm, E.B. Methylmercury and risk in adults - A balanced view, and more 
research, are needed. Environ. Health 2007, 6, 31. 
77.  Rissanen, T.; Voutilainen, S.; Nyyssonen, K.; Lakka, T.A.; Salonen, J.T. Fish oil-derived fatty 
acids, docosahexaenoic acid and docosapentaenoic acid, and the risk of acute coronary events: the 
Kuopio ischaemic heart disease risk factor study. Circulation 2000, 102, 2677-2679. 
78.  Levander, O.A. A global view of human selenium nutrition. Annu. Rev. Nutr. 1987, 7, 227-250. Int. J. Environ. Res. Public Health 2009, 6                 
 
1914 
79.  Holben, D.H.; Smith, A.M. The diverse role of selenium within selenoproteins: a review. J. Am. 
Diet. Assoc. 1999, 99, 836-843. 
80.  Brown, K.M.; Arthur, J.R. Selenium, selenoproteins and human health: a review. Public Health 
Nutr. 2001, 4, 593-599. 
81.  National  Institutes of  Health;  Office  of  Dietary  Supplements.  Dietary  supplement  fact  sheet: 
Selenium. Available online: http://ods.od.nih.gov/factsheets/selenium.asp (accessed January 14, 
2008). 
82.  Li,  J.M.;  Shah,  A.M.  Endothelial  cell  superoxide  generation:  regulation  and  relevance  for 
cardiovascular  pathophysiology.  Am.  J.  Physiol.  Regul.  Integr.  Comp.  Physiol.  2004,  287, 
R1014-1030. 
83.  Huang, K.; Liu, H.; Chen, Z.; Xu, H. Role of selenium  in cytoprotection against cholesterol 
oxide-induced vascular damage in rats. Atherosclerosis 2002, 162, 137-144. 
84.  Traulsen, H.; Steinbrenner, H.; Buchczyk, D.P.; Klotz, L.O.; Sies, H. Selenoprotein P protects 
low-density lipoprotein against oxidation. Free Radic. Res. 2004, 38, 123-128. 
85.  Tanguy, S.; Boucher, F.; Besse, S.; Ducros, V.; Favier, A.; de Leiris, J. Trace elements and 
cardioprotection:  increasing  endogenous  glutathione  peroxidase  activity  by  oral  selenium 
supplementation in rats limits reperfusion-induced arrhythmias. J. Trace Elem. Med. Biol. 1998, 
12, 28-38. 
86.  Tanguy, S.; Toufektsian, M.C.; Besse, S.; Ducros, V.; De Leiris, J.; Boucher, F. Dietary selenium 
intake affects cardiac susceptibility to ischaemia/reperfusion in male senescent rats. Age Ageing 
2003, 32, 273-278. 
87.  Tanguy, S.; Morel, S.; Berthonneche, C.; Toufektsian, M.C.; de Lorgeril, M.; Ducros, V.; Tosaki, 
A.; de Leiris, J.; Boucher, F. Preischemic selenium status as a major determinant of myocardial 
infarct size in vivo in rats. Antioxid. Redox. Signal 2004, 6, 792-796. 
88.  Ayaz, M.; Ozdemir, S.; Ugur, M.; Vassort, G.; Turan, B. Effects of selenium on altered mechanical 
and electrical cardiac activities of diabetic rat. Arch. Biochem. Biophys. 2004, 426, 83-90. 
89.  Ayaz,  M.;  Can,  B.;  Ozdemir,  S.;  Turan,  B.  Protective  effect  of  selenium  treatment  on 
diabetes-induced myocardial structural alterations. Biol. Trace Elem. Res. 2002, 89, 215-226. 
90.  Longnecker, M.P.; Stram, D.O.; Taylor, P.R.; Levander, O.A.; Howe, M.; Veillon, C.; McAdam, 
P.A.; Patterson, K.Y.; Holden, J.M.; Morris, J.S.; Swanson, C.A.; Willett, W.C. Use of selenium 
concentration in whole blood, serum, toenails, or urine as a surrogate measure of selenium intake. 
Epidemiology 1996, 7, 384-390. 
91.  Hunter, D.J.; Morris, J.S.; Chute, C.G.; Kushner, E.; Colditz, G.A.; Stampfer, M.J.; Speizer, F.E.; 
Willett, W.C. Predictors of selenium concentration in human toenails. Am. J. Epidemiol. 1990, 
132, 114-122. 
92.  Flores-Mateo, G.; Navas-Acien, A.; Pastor-Barriuso, R.; Guallar, E. Selenium and coronary heart 
disease: a meta-analysis. Am. J. Clin. Nutr. 2006, 84, 762-773. 
93.  Yoshizawa,  K.;  Ascherio,  A.;  Morris,  J.S.;  Stampfer,  M.J.;  Giovannucci,  E.;  Baskett,  C.K.; 
Willett, W.C.; Rimm, E.B. Prospective study of selenium levels in toenails and risk of coronary 
heart disease in men. Am. J. Epidemiol. 2003, 158, 852-860. Int. J. Environ. Res. Public Health 2009, 6                 
 
1915 
94.  Tribble,  D.L.  AHA  Science  Advisory.  Antioxidant  consumption  and  risk  of  coronary  heart 
disease:  emphasison  vitamin  C,  vitamin  E,  and  beta-carotene:  A  statement  for  healthcare 
professionals from the American Heart Association. Circulation 1999, 99, 591-595. 
95.  Burk, R.F. Selenium, an antioxidant nutrient. Nutr. Clin. Care 2002, 5, 75-79. 
96.  Levander, O.A. Selenium requirements as discussed in the 1996 joint FAO/IAEA/WHO expert 
consultation on trace elements in human nutrition. Biomed. Environ. Sci. 1997, 10, 214-219. 
97.  Parizek,  J.;  Ostadalova,  I.  The  protective  effect  of  small  amounts  of  selenite  in  sublimate 
intoxication. Experientia 1967, 23, 142-143. 
98.  Ganther,  H.E.;  Goudie,  C.;  Sunde,  M.L.;  Kopecky,  M.J.;  Wagner,  P.  Selenium:  relation  to 
decreased  toxicity  of  methylmercury  added  to  diets  containing  tuna.  Science  1972,  175, 
1122-1124. 
99.  Skerfving, S. Interaction between selenium and methylmercury. Environ. Health Perspect 1978, 
25, 57-65. 
100.  Ganther, H.E. Modification of methylmercury toxicity and metabolism by selenium and vitamin E: 
possible mechanisms. Environ. Health Perspect 1978, 25, 71-76. 
101.  Cuvin-Aralar,  M.L.;  Furness,  R.W.  Mercury  and  selenium  interaction:  a  review.  Ecotoxicol. 
Environ. Saf. 1991, 21, 348-364. 
102.  Watanabe, C. Modification of mercury toxicity by selenium: practical importance? Tohoku. J. Exp. 
Med. 2002, 196, 71-77. 
103.  Stoewsand,  G.S.;  Bache,  C.A.;  Lisk,  D.J.  Dietary  selenium  protection  of  methylmercury 
intoxication of Japanese quail. Bull. Environ. Contam. Toxicol. 1974, 11, 152-156. 
104. Iwata, H.; Masukawa, T.; Kito, H.; Hayashi, M. Degradation of methylmercury by selenium. Life 
Sci. 1982, 31, 859-866. 
105.  Iwata, H.; Masukawa, T.; Kito, H.; Hayashi, M. Degradation of methylmercury by selenium. Life 
Sci. 1982, 31, 859-866. 
106.  Goyer, R.A. Nutrition and metal toxicity. Am. J. Clin. Nutr. 1995, 61, 646S-650S. 
107.  El-Demerdash,  F.M.  Effects  of  selenium  and  mercury  on  the  enzymatic  activities  and  lipid 
peroxidation in brain, liver, and blood of rats. J. Environ. Sci. Health B 2001, 36, 489-499. 
108.  Frisk,  P.;  Wester,  K.;  Yaqob,  A.;  Lindh,  U.  Selenium  protection  against  mercury-induced 
apoptosis and growth inhibition in cultured K-562 cells. Biol. Trace Elem. Res. 2003, 92, 105-114. 
109.  Sasakura, C.; Suzuki, K.T. Biological interaction between transition metals (Ag, Cd and Hg), 
selenide/sulfide and selenoprotein P. J. Inorg. Biochem. 1998, 71, 159-162. 
110.  Seppanen,  K.;  Kantola,  M.;  Laatikainen,  R.;  Nyyssonen,  K.;  Valkonen,  V.P.;  Kaarlopp,  V.; 
Salonen, J.T. Effect of supplementation with organic selenium on mercury status as measured by 
mercury in pubic hair. J. Trace. Elem. Med. Biol. 2000, 14, 84-87. 
111.  Buettner, C. Mercury and the risk of myocardial infarction. N. Engl. J. Med. 2003, 348, 2151-2154. 
112.  Aylward, L.L.; Hays, S.M. Temporal trends in human TCDD body burden: decreases over three 
decades  and  implications  for  exposure  levels.  J.  Expo.  Anal.  Environ.  Epidemiol.  2002,  12, 
319-328. 
113.  Hites, R.A.; Foran, J.A.; Carpenter, D.O.; Hamilton, M.C.; Knuth, B.A.; Schwager, S.J. Global 
assessment of organic contaminants in farmed salmon. Science 2004, 303, 226-229. Int. J. Environ. Res. Public Health 2009, 6                 
 
1916 
114.  Foran,  J.A.;  Good,  D.H.;  Carpenter,  D.O.;  Hamilton,  M.C.;  Knuth,  B.A.;  Schwager,  S.J. 
Quantitative analysis of the benefits and risks of consuming farmed and wild salmon. J. Nutr. 
2005, 135, 2639-2643. 
115.  Schecter, A.; Cramer, P.; Boggess, K.; Stanley, J.; Papke, O.; Olson, J.; Silver, A.; Schmitz, M. 
Intake of dioxins and related compounds from food in the U.S. population. J. Toxicol. Environ. 
Health A 2001, 63, 1-18. 
116.  Judd, N.; Griffith, W.C.; Faustman, E.M. Contribution of PCB exposure from fish consumption to 
total dioxin-like dietary exposure. Regul. Toxicol. Pharmacol. 2004, 40, 125-135. 
 
© 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This 
article is an open-access article distributed under the terms and conditions of the Creative Commons 
Attribution license (http://creativecommons.org/licenses/by/3.0/). 